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Basal intracellular guanosine 3',5'-cyclic monosphosphate
(cGMP) levels and the pattern of cGMP accumulation and
degradation after guanylyl cyclase stimulation are strongly
influenced by the presence of different cGMP hydrolysing
phosphodiesterases (PDEs).
At least 21 PDE genes have been identified and sub-
grouped into 11 families. PDE4, PDE7 and PDE8 prefer-
entially hydrolyse adenosine 3',5'-cyclic monosphosphate
(cAMP), while PDE5, PDE6 and PDE9 hydrolyse cGMP
and PDE1, PDE2, PDE3, PDE10 and PDE11 can hydro-
lyse both cAMP and cGMP. These enzymes show a distinct
regional, cellular and subcellular distribution pattern that
can change during development and cellular activity.
We have determined the relative mRNA expression levels
of the cGMP metabolising phosphodiesterases PDE5,
PDE9 (cGMP specific), PDE2, PDE10 (hydrolyse both
cGMP and cAMP) in 24 different human tissues using
quantitative real time PCR. Pooled RNA samples derived
from at least 4 donors were used for cDNA synthesis.
Three housekeeping genes were used as internal stand-
ards. Primers were designed to amplify cDNA regions that
are present in all known splicing isoforms, optimised and
used for quantitative real time PCR (ABI PRISM 7900HT,
SYBR Green detection method).
PDE10 mRNA showed the most striking differential distri-
bution, with very high levels in caudate nucleus and n.
accumbens, at least 20 fold lower levels in thalamus, cer-
ebellum, hippocampus, various cortical regions and sub-
stantia nigra and generally very low expression in different
peripheral tissues. PDE2 was highly expressed in spleen,
caudate nucleus, cortex, hippocampus and nucleus
accumbens with lower levels in adrenal gland, bladder,
thalamus and hypothalamus. Of the 24 tissues examined,
PDE5 showed highest expression levels in lung, followed
by bladder, heart, small intestine, dorsal root ganglia and
lower but significant levels in most other tissues. The lev-
els of PDE9 mRNA showed less variation between differ-
ent tissues. Most tissues showed between 30 and 70 % of
the highest signal, which was found in bladder. Lowest
levels of PDE9 mRNA were present in heart, liver and skel-
etal muscle (5–10% of the maximum signal).
Our data confirm and extend earlier studies using in situ
hybridisation, Northern Blot or PCR analysis in rat,
mouse and human tissues and are consistent with the dis-
tribution pattern for PDE10 protein in rat brain that was
determined by immunohistochemistry [1].
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